Ned Biosystems, Inc

Founded to allow patients to achieve and sustain No Evidence of Disease NED Biosystems™ was founded to develop safe, efficacious, and comprehensive “systems” treatments for complex disease, beginning with the development of the patented NED-170 for treatment of cancer. A systems-based approach to treat disease comprehensively targets the behavior of the entire biological system instead of a single component. We begin with a focus on patients and their families. NED seeks to dramatically improve patients’ outcomes with treatments that lack the toxicity and side effects of today’s treatments, allowing patients a high quality of life. NED-170 takes a systems approach that combines repurposed, oral agents well-documented in humans to affect critical cancer disease-driver processes at doses that lack customary toxicity and side effects. 50%-80% of all cancer patients have no genetically sequenced “matched” therapy options. NED-170 is designed to initially treat these patients. When the pandemic hit NED deployed its systems methodology to develop NED-260 to be a universal antiviral treatment for existing infectious diseases and those not yet known. NED-260 is designed to protect multiple pathways within patients’ cells from attack by a broad range of viruses. NED-260’s treatment goal is to act early in the infection process to minimize, or eliminate, the advancement to severe disease, ideally allowing many patients to recover at home.